Company intelligence
MedPharm
Topical & Transepithelial CDMO | From Concept to Commercialization
About MedPharm
For more than 25 years, MedPharm has helped pharmaceutical and biotechnology companies turn innovative ideas into successful topical and transepithelial drug products. As a leading CDMO, we partner with sponsors from concept through commercialization, combining scientific expertise with integrated development and manufacturing capabilities to reduce risk, accelerate timelines, and improve the likelihood of success. Our expertise spans multiple routes of administration, including: • Skin • Nail • Eye • Nasal & Pulmonary • Mucosal • Other specialized epithelial delivery routes What makes MedPharm different is our integrated approach. Formulation development is guided by a proprietary toolbox of predictive, human-relevant preclinical models that allow us to evaluate formulation performance, target engagement, local pharmacokinetics, pharmacodynamics, and biological activity under physiologically relevant conditions. By generating meaningful data early, we help sponsors make confident development decisions before costly challenges arise. Every biological barrier is different, so every formulation strategy is purpose-built. Our scientists develop products with the target tissue, manufacturing process, and commercial success in mind from day one, creating a seamless path from formulation development through scale-up, clinical trial material manufacturing, and commercial GMP production. Our capabilities also include: • Formulation Development • Analytical & Bioanalytical Services • IVRT & IVPT • Device & Combination Product Development • Stability Studies • Clinical Trial Material Manufacturing • Commercial GMP Manufacturing With facilities in the United States and the United Kingdom, plus our partnership with Purna Pharmaceuticals in Belgium, MedPharm provides flexible global development and manufacturing solutions for innovators bringing the next generation of medicines to patients.
Verified activity
Signals from MedPharm
1 published signal